FR2845383B1 - Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique - Google Patents

Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique

Info

Publication number
FR2845383B1
FR2845383B1 FR0212368A FR0212368A FR2845383B1 FR 2845383 B1 FR2845383 B1 FR 2845383B1 FR 0212368 A FR0212368 A FR 0212368A FR 0212368 A FR0212368 A FR 0212368A FR 2845383 B1 FR2845383 B1 FR 2845383B1
Authority
FR
France
Prior art keywords
thiohydantoin
therapeutics
compounds derived
derived
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0212368A
Other languages
English (en)
Other versions
FR2845383A1 (fr
Inventor
Benaissa Boubia
Khan Ou
Evelyne Chaput
Didier Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratories Fournier SAS
Original Assignee
Laboratories Fournier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0212368A priority Critical patent/FR2845383B1/fr
Application filed by Laboratories Fournier SAS filed Critical Laboratories Fournier SAS
Priority to EP03772390A priority patent/EP1546111A2/fr
Priority to PCT/FR2003/002904 priority patent/WO2004031160A2/fr
Priority to JP2004540883A priority patent/JP2006510600A/ja
Priority to AU2003279442A priority patent/AU2003279442A1/en
Priority to CA002500977A priority patent/CA2500977A1/fr
Priority to US10/529,817 priority patent/US20060025589A1/en
Publication of FR2845383A1 publication Critical patent/FR2845383A1/fr
Application granted granted Critical
Publication of FR2845383B1 publication Critical patent/FR2845383B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
FR0212368A 2002-10-01 2002-10-04 Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique Expired - Fee Related FR2845383B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0212368A FR2845383B1 (fr) 2002-10-04 2002-10-04 Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
PCT/FR2003/002904 WO2004031160A2 (fr) 2002-10-04 2003-10-03 Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete
JP2004540883A JP2006510600A (ja) 2002-10-04 2003-10-03 ２−チオヒダントインに由来する化合物及び治療におけるその使用
AU2003279442A AU2003279442A1 (en) 2002-10-04 2003-10-03 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
EP03772390A EP1546111A2 (fr) 2002-10-04 2003-10-03 Composes derives de la 2-thiohydantoine et leur utilisation pour le traitement du diabete
CA002500977A CA2500977A1 (fr) 2002-10-04 2003-10-03 Composes derives de la 2-thiohydantoine et leur utilisation pour le traitement du diabete
US10/529,817 US20060025589A1 (en) 2002-10-01 2003-10-03 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0212368A FR2845383B1 (fr) 2002-10-04 2002-10-04 Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique

Publications (2)

Publication Number Publication Date
FR2845383A1 FR2845383A1 (fr) 2004-04-09
FR2845383B1 true FR2845383B1 (fr) 2004-12-31

Family

ID=32011423

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0212368A Expired - Fee Related FR2845383B1 (fr) 2002-10-01 2002-10-04 Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique

Country Status (1)

Country Link
FR (1) FR2845383B1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA786739B (en) * 1977-12-01 1980-07-30 Wellcome Found Hydantoin derivatives and salts thereof,their syntheses,and intermediates,and pharmaceutical formulations
US4743611A (en) * 1986-07-02 1988-05-10 American Home Products Corp. Naphthalenylsulfonylimidazolidinediones and their thioxo analogs useful as aldose reductase inhibitors
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
EP0721944B1 (fr) * 1994-07-29 2001-01-17 Suntory Limited Derives d'imidazolidine et son utilisation
NZ517993A (en) * 1999-08-31 2004-03-26 Incyte San Diego Inc Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes

Also Published As

Publication number Publication date
FR2845383A1 (fr) 2004-04-09

Similar Documents

Publication Publication Date Title
FR21C1056I2 (fr) Composes de thienopyrimidine et utilisation
FR2823209B1 (fr) Nouvelles thiohydantoines et leur utilisation en therapeutique
MA28758B1 (fr) Composes d'aminoalkylglucosaminide phosphate et leur utilisation
IL164400A0 (en) Deruvatuves if n-Äphenyl(piperidin-2-yl)methylÜbenzamide, the preparation method thereof and application of same in therapeutics
EP1541585A4 (fr) Antagoniste de cxcr4 et son utilisation
EG23770A (en) Thin and dry diaper
PT2702871T (pt) Biotecido de colagénio e sua utilização
PT1419150E (pt) Derivados de 1-fenilsulfonil-1,3-di-hidro-2h-indol-2-ona, sua preparacao e sua aplicacao em terapeutica
MA26348A1 (fr) 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine substituees et leur utilisation
DE60304737D1 (de) Verbesserungen bei rauchartikeln
DE60118618D1 (de) Gelartiger polymerelektrolyt und zugehörige verwendung
DE60329138D1 (de) Geldautomat
HK1077853A1 (zh) 彈性織維及其用途
FR2845384B1 (fr) Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR2869217B1 (fr) Implant glenoidien pour prothese totale d'epaule inversee, et prothese totale d'epaule inversee le comprenant
PT1513836E (pt) Derivados de piperazinilacilpiperidina, sua preparacao e sua aplicacao em terapeutica
EP1674498A4 (fr) Copolymere a blocs et utilisation
DE60309952D1 (de) Geldautomat
FI20021149A0 (fi) Sondijärjestelmä, sondijärjestelmän vastaanotin sekä signaalinkäsittelymenetelmä sondivastaanottimessa
GB0323954D0 (en) Block copolymer and use thereof
GB0308860D0 (en) Game system and game program
NO20031332D0 (no) Arylalkan-sulfonamider med endothelin-antagonistaktivitet
FR2845385B1 (fr) Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
AU2003272606A8 (en) Distance measuring systems and methods thereof
FR2845383B1 (fr) Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20070629